Loading…

Medical Research Finder

Gut microbiota / Evidence-based microbiome knowledge (incl. AI chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

Adverse Events / Safety & Anti-PD-1 antibodies / PD-1 inhibitors

Welcome to meRfi-GM!

Please register to continue your trial period!

meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody
Maher et al. 2019 JCO 37: 2730-2737
Hyperprogressive disease with anti-PD-1 and anti-PD-L1
Brower 2016
Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials
Sonpavde et al. 2021
Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
Naidoo et al., 2017 JCO 35: 709-717
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
Topalian et al. 2012 N Engl J Med. 366(26): 2443–54
The safety of anti PD-1 therapeutics for the treatment of melanoma
Ramelyte et al., 2017
Review
Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis
Zhou et al. 2021d The Lancet Oncology 22: 1265-1274
Meta-Analysis
Review

5/29/2026